“…Since the isolation and structural elucidation of the two fungal secondary metabolites,p homoidride A( 1;C P-225,917) and phomoidride B( 2;C P-263, 114;F igure 1), by researchers at Pfizer, [1] numerous groups have devoted efforts toward developing new synthetic strategies to construct these natural products. [2] While the cholesterol-lowering and anticancer properties displayed by 1 and 2 certainly motivated synthetic efforts,t here is little doubt that the unique and complex architecture inherent to the phomoidrides has served as the primary inspiration to what has proven to be avariety of markedly creative approaches, [2,3] and four completed total syntheses. [4] Studies toward these targets also led to the discovery of two other congeners,p homoidride Ca nd phomoidride D( 3 and 4,r espectively,F igure 1), [4f, 5] which differ in the relative stereochemistry at C7.…”